SCHEMBL2220259

SCHEMBL2220259

CCN(C(=O)O)c1cccc(Cc2nn(-c3cc(F)cc(F)c3)ccc2=O)c1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.36
LMNA P02545 2/20 0.35
RXFP1 Q9HBX9 2/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
PDE10A Q9Y233 1/20 0.34
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
JAK2 O60674 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32
PAX8 Q06710 1/20 0.32
KDM4E B2RXH2 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PTGDR2 Q9Y5Y4 3/20 0.32
KAT6A Q92794 1/20 0.32
CYP2C9 P11712 1/20 0.32
RIPK1 Q13546 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223717 0.92 KMT2A (0.33) TP53KMT2AMEN1PDE10ARAB9A
SCHEMBL2221519 0.91 TP53 (0.35) TP53LMNARXFP1KMT2AMEN1
SCHEMBL2222078 0.91 ELOVL1 (0.38) TP53LMNARXFP1
SCHEMBL2220117 0.90 CYP2C9 (0.41) TP53RXFP1KMT2AMEN1PDE10A
SCHEMBL13507151 0.90 KMT2A (0.33) KMT2AMEN1PDE10ARAB9ANPC1
SCHEMBL13274535 0.89 TP53 (0.37) TP53LMNARXFP1KMT2AMEN1
SCHEMBL13275659 0.88 KDM4E (0.34) KMT2AMEN1PDE10ARAB9AALDH1A1
SCHEMBL2271255 0.88 PDE10A (0.33) TP53KMT2AMEN1PDE10ARAB9A
SCHEMBL2221742 0.87 KDM4E (0.32) KMT2AMEN1PDE10AKDM4EL3MBTL1
SCHEMBL2222072 0.86 MEN1 (0.39) TP53RXFP1KMT2AMEN1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US claimed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO claimed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 TP53 190/4885LMNA 4501/4885RXFP1 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.